[Guoxin Securities] Zhongheng Group: Cooperating with Kangmei in supply chain, channel and medical services to unleash the company's huge potential
[Changjiang Securities] Zhongheng Group: After deducting high growth in performance, product introduction continues
[CIC Securities] Zhongheng Group: Xueshuantong is growing steadily, and the extension strategy continues to advance.
[Changjiang Securities] Zhongheng Group: rapid growth in performance and strong extension expectation
[CIC Securities] Zhongheng Group: performance in line with expectations, implementation of overseas new drug introduction strategy
[southwest Securities] comments on the 2014 annual report of Zhongheng Group: the sales volume of Xuantong for injection is stable, and the net profit is growing high.
[CIC Securities] Zhongheng Group: comments on the results of Drug bidding in Hunan Province
[CIC Securities] Zhongheng Group: Xueshuantong growth is in line with expectations, reducing holdings of Guohai to increase net profit
[CIC Securities] Zhongheng Group: high performance growth is guaranteed, waiting for valuation repair
[Changjiang Securities] Zhongheng Group: strong endogenous growth, Panax notoginseng price reduction and thickening performance
[Northeast Securities] Zhongheng Group: The main business surged by 43.24% in the first three quarters, and Q3 accelerated markedly
[Guoxin Securities] Zhongheng Group's 2014 3rd Quarterly Report Review: Strong endogenous growth, expectations for extension, majority shareholders' participation will definitely increase confidence
[Huatai Securities] Zhongheng Group: Thrombophilia continues to grow at a high rate, and the pace of extension accelerates
[Fangzheng Securities] Zhongheng Group: Performance is in line with expectations, March 7 price declines will continue to improve profitability
[Southwest Securities] Zhongheng Group 2014 Three Quarterly Report Review: Net profit increased rapidly in the first three quarters, exceeding market expectations
[China Investment Securities] Zhongheng Group: High blood pressure continues to grow, and the increase in net profit after deducting non-net profit exceeds expectations
[China Investment Securities] Zhongheng Group: Zhejiang Pharmaceutical Centralized Procurement Implementation Plan (Draft for Comments) Comments
[Lianxun Securities] Zhongheng Group's semi-annual report review: The pharmaceutical business is growing steadily, and the expansion of mergers and acquisitions is expected to accelerate
[Huatai Securities] Zhongheng Group: The growth rate has slowed due to fee control, and we are looking forward to extension expansion
[Guoxin Securities] - Zhongheng Group: Endogenous growth continues to be strong, looking forward to accelerated extension
No Data